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Abstract
Background: Nuclear texture analysis measuring differences in chromatin structure has provided prognostic biomarkers in
several cancers. There is a need for improved cell-by-cell chromatin analysis to detect nuclei with highly disorganized chro-
matin. The purpose of this study was to develop a method for detecting nuclei with high chromatin entropy and to evaluate
the association between the presence of such deviating nuclei and prognosis.
Methods: A new texture-based biomarker that characterizes each cancer based on the proportion of high–chromatin entropy
nuclei (<25% vs 25%) was developed on a discovery set of 175 uterine sarcomas. The prognostic impact of this biomarker
was evaluated on a validation set of 179 uterine sarcomas, as well as on independent validation sets of 246 early-stage ovar-
ian carcinomas and 791 endometrial carcinomas. More than 1 million images of nuclei stained for DNA were included in the
study. All statistical tests were two-sided.
Results: An increased proportion of high–chromatin entropy nuclei was associated with poor clinical outcome. The biomarker
predicted five-year overall survival for uterine sarcoma patients with a hazard ratio (HR) of 2.02 (95% confidence interval [CI]
¼ 1.43 to 2.84), time to recurrence for ovarian cancer patients (HR ¼ 2.91, 95% CI ¼ 1.74 to 4.88), and cancer-specific survival
for endometrial cancer patients (HR ¼ 3.74, 95% CI ¼ 2.24 to 6.24). Chromatin entropy was an independent prognostic marker
in multivariable analyses with clinicopathological parameters (HR ¼ 1.81, 95% CI ¼ 1.21 to 2.70, for sarcoma; HR ¼ 1.71, 95% CI
¼ 1.01 to 2.90, for ovarian cancer; and HR ¼ 2.03, 95% CI ¼ 1.19 to 3.45, for endometrial cancer).
Conclusions: A novel method detected high–chromatin entropy nuclei, and an increased proportion of such nuclei was asso-
ciated with poor prognosis. Chromatin entropy supplemented existing prognostic markers in multivariable analyses of three
gynecological cancer cohorts.
Genomic instability is central in the multistep development of
cancer (1,2), and the assessment of large-scale genomic altera-
tions in cancer cell nuclei is useful for predicting clinical out-
comes in cancer patients (3). There is a complex relation
between genomic alterations and large-scale rearrangement of
interphase nuclear chromatin. Chromatin structure is central in
both transcriptional regulation and maintenance of genomic
stability (4). Chromatin is continually remodeled, and targeted
chromatin remodeling determines transcriptional control (5).
Modification of chromatin structure also has a regulatory
function in DNA repair, replication, and chromosome
segregation (5).
Nuclear texture analysis (Nucleotyping) refers to the charac-
terization of chromatin structure based on digital microscope
images of cell nuclei (6). Prior to imaging, the nuclei are stained
with a DNA-specific stain, and the gray levels in the images
thus correspond to DNA content. Nucleotyping describes the
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the spatial arrangement of the pixel gray levels in small subre-
gions of the nuclear images. Entropy is very useful for such
quantification of local heterogeneity in the chromatin structure
(6–8) and is found to be a prognostic marker in several gyneco-
logical cancers (9–11). The Nucleotyping biomarker used in
these previous studies was based on average values computed
from all measured nuclei from a patient, and was therefore
influenced by the majority of the nuclei. It is generally accepted
that subpopulations of cells constitute the driving force and
have the ability to metastasize during carcinogenesis, and
therefore there is a need for improved cell-by-cell chromatin
analysis (1,3,9).
The aim of the present study was to test the hypotheses that
there exists a subpopulation of cells with high chromatin
entropy and that there is an association between the presence




A total of 587 uterine sarcomas were registered from 1970 to
2000 at the Norwegian Cancer Registry, which gathers informa-
tion on all cancer events in Norway (12). Survival dates were
provided by the Cancer Registry on October 31, 2007, for all
patients. The tumors were reclassified by an experienced gyne-
cological pathologist according to World Health Organization
(WHO) recommendations (13), and the diagnosis of uterine sar-
coma was confirmed in 419 patients (12). Tissue samples from
354 patients were available for analysis (Supplementary Figure
1A, available online) (10,14). This study was approved by the
Regional Ethics Committee (REK, No. S-04298), which also ap-
proved the decision to not obtain written informed consent for
deceased patients.
Early-Stage Ovarian Cancer
Another study included tissue samples from 246 patients treated
during 1982–1989 for ovarian cancer classified as International
Federation of Gynecology and Obstetrics (FIGO) stage I
(Supplementary Figure 1B, available online) (11). Generally, surgery
was performed at county hospitals, and the patients were admit-
ted to The Norwegian Radium Hospital for evaluation and further
treatment. All patients were followed up until death or December
31, 1998. Follow-up information was also achieved from the
National Statistical Bureau, which keeps records of all inhabitants
in Norway (15). All histological sections were reviewed by a single
pathologist, and the histological classification was performed us-
ing WHO criteria (15). The study was in accordance with
Norwegian law, which at the time did not require written in-
formed consent to analyze this type of anonymized data.
Endometrial Cancer
A total of 1046 endometrial cancer patients from the interna-
tional multicenter trial Molecular Markers in Treatment of
Endometrial Cancer (MoMaTEC1, Clinical Trial identifier
NCT00598845) were treated in the period from 2001 to 2012. Of
these, 402 patients were treated at the Haukeland University
Hospital, Norway, and 644 patients were included from nine
other hospitals. Information about cancer-specific survival was
collected from patient records and correspondence with physi-
cians responsible for outpatient follow-up (16). As described
earlier, 791 patients were available for analysis (Supplementary
Figure 1C, available online) (9). The last follow-up date for these
patients was September 12, 2013. Written informed consent
was obtained from all patients. The study was approved by REK
(REKIII No. 052.01).
Discovery and Validation Cohorts
Uterine sarcomas were divided into discovery (175 patients) and
validation (179 patients) data sets (Supplementary Materials,
available online) (10). In order to design a classifier for prognos-
tication of cancer patients, the discovery set was grouped into
two prognostic classes. The patients who survived for at least
five years were defined as good prognosis, whereas the patients
who died within five years were defined as poor prognosis (10).
The methodology was developed on the discovery set and
then the trained classifier was evaluated on the corresponding
validation set, and further evaluated on the independent valida-
tion sets of ovarian and endometrial cancer. As we have previ-
ously shown that nuclear texture varies with nuclear area and
that prognostication could be enhanced by grouping the nuclear
images by their areas (17), the biomarker was computed using
only nuclei within a certain size range (nuclear area between
54 mm2 and 134 mm2), involving 158 868 and 844 003 nuclei in the
discovery and validation sets, respectively (Supplementary
Materials, available online). Sample preparation and imaging
are described in the Supplementary Materials (available online).
Nuclear Texture Analysis
Each pixel in a nuclear image was characterized by the gray
level of the pixel and the entropy computed from the gray levels
in a small neighborhood around the pixel (Figure 1, A–C). The
occurrence of pairs of gray level and entropy values in the nu-
cleus was counted and accumulated in a gray level entropy ma-
trix and then normalized by dividing each element by the total
number of nuclear pixels (Figure 1D; Supplementary Materials,
available online).
We propose to characterize a given gray level entropy matrix
by the center of mass of the distribution (center of mass in gray
level and entropy) together with the concentration measure rel-
ative matrix area, containing the peak(s) of the distribution
(Figure 1, D–F; Supplementary Materials, available online).
These three features were computed for all nuclei representing
a patient, resulting in a 3D feature plot for each patient
(Figure 1, G and H).
In the design phase of the novel biomarker, center of mass
in gray level and entropy and relative matrix area were com-
puted from all nuclei in the discovery set, and the resulting 3D
feature space was clustered into five subgroups by k-means
clustering. Each cluster corresponds to points with similar fea-
ture values (ie, similar chromatin texture), and the clusters
were sorted according to increasing mean relative matrix area
(ie, clusters 1–5 represented nuclei with increasing chromatin
entropy) (Supplementary Figure 2, available online). Cluster 5,
which contained 10.8% of the nuclei, was defined to represent
the high–chromatin entropy nuclei.
The biomarker classifies each patient as low or high chroma-
tin entropy based on the proportion of high–chromatin entropy
nuclei (Figure 1H). The threshold of 25% was selected based on
training in the discovery set (Supplementary Materials and


















The clinical end points were the same as used in previous stud-
ies on the same materials and different for the three materials.
In the uterine sarcoma material, overall survival (OS) was calcu-
lated from date of diagnosis to death or end of (five-year)
follow-up (10). In the ovarian cancer material, time to recur-
rence (TTR) was calculated from start of treatment to relapse or
end of the study period (11,15). The cancer-specific survival
(CSS) in the endometrial cancer material was calculated from
primary treatment to last follow-up or death (9,16). The end
points were defined as proposed by Punt et al. (18). A subse-
quent analysis of overall survival of uterine sarcomas without
truncating at five years was also performed. As we consider
cancer-specific survival to be the clinically most relevant end
point common to all three cohorts, we also performed subse-
quent analyses using CSS as the end point for the uterine sar-
coma and ovarian cancer cohorts. The Mantel-Cox log-rank test
Figure 1. Quantification of chromatin entropy. A) A digital image of a cell nucleus. B) A quadratic window (1515 pixels) is centered on each pixel in the nucleus, and
then the pixel is characterized by the gray level i (eg, i ¼ 42) and the entropy j computed from the gray levels included in the window (eg, j ¼ 3.1), where P(i) is the nor-
malized frequency of gray level i within the window. C) Gray levels in a subregion of the window. D) The i and (quantified) j values are used as indices in a two-way ta-
ble, named a gray level entropy matrix (GLEM), and the frequencies of different (i,j) combinations are accumulated. The final GLEM is normalized by dividing each
element in the table by the total number of nuclear pixels, providing a bivariate probability mass function. E) The probability values in the GLEM were sorted in
descending order and then summed (starting with the highest value) until the total sum was greater than or equal to 0.25. The concentration of the (i,j) values in the
GLEM was measured as the number of matrix elements included in the summation (shown as white pixels) divided by the total number of matrix elements. A smaller
number of white matrix elements corresponds to a condensed GLEM, while a larger number of white matrix elements corresponds to a more scattered GLEM. F) A
three-dimensional feature plot. The coordinates of the point are the center of mass in gray levels and in entropy values computed from the GLEM in (D) and the relative
matrix area from (E). G) The steps shown in (A–F) were performed for all the cell nuclei representing a given patient. H) The data points in the 3D feature space corre-
spond to all measured nuclei from the given patient. Red points correspond to nuclei with high chromatin entropy. Based on the proportion of such nuclei (<25% vs
25%), patients were classified as low chromatin entropy (eg, the patient in Part 1 who had 4.0% nuclei with high chromatin entropy) or high chromatin entropy (eg,
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was used to test equality of survival distributions. The Wald v2
test was used in a Cox proportional hazards model in
multivariable analysis. The assumption of proportionality was
verified using the Schoenfeld residual plot and test, and no ma-
jor model violation was observed. The clinical and pathological
variables included in multivariable analysis on each cohort
were the same as used in previous studies (9–12,14–16).
Backward selection was used in stepwise Cox regression analy-
sis of the uterine sarcoma cohort (exclusion criterion P > .05),
and all excluded variables were eventually tested for model in-
clusion. The Mann-Whitney U test (in MATLAB R2015a) was
used to estimate if there was a statistically significant
Figure 2. Kaplan-Meier survival curves according to the chromatin entropy marker. The curves are based on the complete data sets of (A and B) uterine sarcoma (354
patients), (C and D) ovarian cancer (246 patients), and (E) endometrial cancer (791 patients). The P values were calculated using the two-sided Mantel-Cox log-rank test.
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difference in the proportion of high–chromatin entropy nuclei
between the prognostic groups of each of the three materials.
Associations between variables were evaluated by Spearman
rank correlation. A two-sided P value of less than .05 was con-
sidered statistically significant. Texture analysis was performed
in MATLAB R2015a (The MathWorks, Inc., Natick,
Massachusetts, USA), and survival analysis was performed us-
ing the SPSS statistical package (IBM SPSS Statistics version 23,
IBM Corp., Armonk, NY, USA).
Results
Patient characteristics are given in Supplementary Tables 1–3
(available online). Classification results of the chromatin en-
tropy marker are given in Supplementary Table 4 (available on-
line). Statistics on the proportion of high–chromatin entropy
nuclei for patients in the different prognostic groups are given
in Supplementary Table 5 (available online).
Discovery Cohort
The five-year overall survival of sarcoma patients in the discov-
ery set was statistically significantly lower for high–chromatin
entropy patients compared with low–chromatin entropy
patients (27.6%, 95% confidence interval [CI] ¼ 13.1 to 44.3, vs
57.5%, 95% CI ¼ 49.1 to 65.1, of the patients survived for at least
five years; hazard ratio [HR] ¼ 2.13, 95% CI ¼ 1.30 to 3.49).
Validation Cohorts
Uterine Sarcoma
When evaluated in the sarcoma validation set, there was also a sta-
tistically significant difference in survival between these two pa-
tient groups (28.1%, 95% CI ¼ 14.0 to 44.1, vs 56.5%, 95% CI ¼ 48.1 to
64.0, survived for at least five years; HR ¼ 1.91, 95% CI ¼ 1.18 to
3.08).
The five-year overall survival of all uterine sarcoma patients
was 57.0% (95% CI ¼ 51.1% to 62.4%) for low–chromatin entropy
patients and 27.9% (95% CI ¼ 17.3% to 39.4%) for high–chromatin
entropy patients (HR ¼ 2.02, 95% CI ¼ 1.43 to 2.84) (Fig. 2A).
Chromatin entropy was statistically significant in multivariable
analysis with established clinicopathological variables (HR ¼
1.81, 95% CI ¼ 1.21 to 2.70) (Table 1; Supplementary Table 6, avail-
able online). Supplementary Figure 6 (available online) shows the
prognostic impact of the marker in subgroups of these variables.
Chromatin entropy was also a statistically significant prog-
nostic marker in overall survival (Supplementary Figure 7 and
Supplementary Table 7, available online) and in cancer-specific
survival analyses (Figure 2B; Supplementary Table 8, available
online). There was a positive correlation between proportion of
high–chromatin entropy nuclei and cellular atypia (q ¼ .53, 95%
CI ¼ 0.45 to 0.60, P < .001).
Univariate analyses were performed separately among stage
I leiomyosarcomas. Chromatin entropy could be combined with
mitoses and tumor size to obtain an improved risk classification
with five-year overall survival of 81.6% (95% CI ¼ 67.7% to 90.0%),
47.4% (95% CI ¼ 37.1% to 57.0%), and 9.5% (95% CI ¼ 1.6% to
26.1%), for the low-, medium-, and high-risk groups, respectively,
compared with 75.0% (95% CI ¼ 62.5% to 83.9%), 45.1% (95% CI ¼
34.2% to 55.5%), and 10.5% (95% CI ¼ 1.8% to 28.4%), for an earlier
proposed risk stratification defined by mitoses and tumor size
(Figure 3) (12).
Early-Stage Ovarian Cancer
The recurrence rate of ovarian cancer was statistically signif-
icantly higher for high–chromatin entropy patients
compared with low–chromatin entropy patients (HR ¼ 2.91,
95% CI ¼ 1.74 to 4.88; 55.6%, 95% CI ¼ 40.4% to 72.0%, vs 24.9%,
95% CI ¼ 19.6% to 31.4%, of the patients relapsed within ten
years) (Figure 2C).
Chromatin entropy was an independent prognostic marker
in multivariable analysis with histological grade and FIGO stage
(HR ¼ 1.71, 95% CI ¼ 1.01 to 2.90) (Table 2). Supplementary
Figure 8 (available online) shows the prognostic impact of the
marker in subgroups of FIGO stage and histological grade, in ad-
dition to subgroups of a clinically relevant risk stratification de-
fined by stage and grade (19,20). Among patients classified as
high risk by stage and grade, the time to recurrence was statisti-
cally significantly shorter for high–chromatin entropy patients
compared with low–chromatin entropy patients (ten-year time
to recurrence was 36.7%, 95% CI ¼ 20.1% to 53.4%, vs 57.2%, 95%
CI ¼ 47.0% to 66.2%) (Figure 4B). In the combined low/medium-
risk group, there was no statistically significant difference in re-
currence between low– and high–chromatin entropy patients
(Figure 4A).
Table 1. Multivariable five-year overall survival analysis of the chro-
matin entropy marker and established clinicopathological variables
among 354 uterine sarcomas
Feature HR (95% CI) P*
Chromatin entropy .004
Low chromatin entropy Ref
High chromatin entropy 1.81 (1.21 to 2.70)
Histological subtype .01
Leiomyosarcoma Ref
Endometrial stromal sarcoma 0.59 (0.28 to 1.23)
Adenosarcoma 1.38 (0.52 to 3.70)
Undifferentiated uterine sarcoma 0.62 (0.26 to 1.47)
Other sarcomas 2.68 (1.39 to 5.15)
Mitotic index, high-power field <.001
10 Ref
>10 2.49 (1.70 to 3.63)
Tumor extent <.001
Confined to the uterus Ref
Spread outside the uterus 2.57 (1.74 to 3.80)
Tumor size, cm .001
10 Ref
>10 1.88 (1.28 to 2.77)
Tumor margins .24
Pushing Ref
Infiltrating 1.30 (0.84 to 2.02)
Cellular atypia .29
Mild Ref
Moderate 1.55 (0.83 to 2.90)
Severe 1.27 (0.66 to 2.46)
Tumor necrosis .17
Absent Ref
Present 1.44 (0.85 to 2.44)
Hyaline necrosis .52
Absent Ref
Present 1.13 (0.78 to 1.62)
Vascular invasion .08
Absent Ref
Present 1.40 (0.97 to 2.01)
*The P values were calculated using the two-sided Wald v2 test. CI ¼ confidence














slo user on 20 D
ecem
ber 2018
Figure 3. Kaplan-Meier five-year overall survival curves among leiomyosarcoma stage I patients. The survival curves are based on (A) chromatin entropy, (B) a risk clas-
sification defined by tumor size and mitoses (12), chromatin entropy within the (C) low-risk, (D) medium-risk, and (E) high-risk groups defined by tumor size and mito-
ses, and (F) a novel risk classification defined by tumor size, mitoses, and chromatin entropy. Risk classification defined by tumor size and mitoses: low risk: tumor size
 10 cm and MI  10 per high-power field (HPF); medium risk: tumor size  10 cm and MI > 10 per HPF or tumor size > 10 cm and MI  10 per HPF; high risk: tumor size
> 10 cm and MI > 10 per HPF. Proposed risk classification defined by tumor size, mitoses, and chromatin entropy: low risk: tumor size  10 cm, MI  10 per HPF, and
low chromatin entropy; medium risk: tumor size  10 cm, MI  10 per HPF, and high chromatin entropy or tumor size  10 cm and MI > 10 per HPF or tumor size > 10
cm, MI  10 per HPF, and low chromatin entropy; high risk: tumor size > 10 cm, MI  10 per HPF, and high chromatin entropy or tumor size > 10 cm and MI > 10 per
HPF. The P values were calculated using the two-sided Mantel-Cox log-rank test. *HR of medium risk vs low risk in survival analysis of the three risk groups. †HR of
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Chromatin entropy was also a statistically significant prog-
nostic marker in analysis of cancer-specific survival (Figure 2D;
Supplementary Table 9, available online). There was a positive
correlation between proportion of high–chromatin entropy nu-
clei and histological grade (q ¼ .37, 95% CI ¼ 0.24 to 0.49, P <
.001, clear cell excluded).
Endometrial Cancer
The cancer-specific survival of endometrial cancer patients was
statistically significantly shorter for high–chromatin entropy
tumors compared with low–chromatin entropy tumors (HR ¼
3.74, 95% CI ¼ 2.24 to 6.24); five-year cancer-specific survival
rates were 65.8% (95% CI ¼ 51.3% to 77.0%) and 87.5% (95% CI ¼
83.8% to 90.4%), respectively (Figure 2E).
Chromatin entropy was an independent prognostic marker
in multivariable analysis with the other preoperative available
variables (HR ¼ 2.03, 95% CI ¼ 1.19 to 3.45) (Table 3).
Supplementary Figure 9 (available online) shows the prognostic
impact of the novel marker in subgroups of both preoperative
and postoperative variables. There was a positive correlation
between the proportion of high–chromatin entropy nuclei and
histological grade (q ¼ .42, 95% CI ¼ 0.36 to 0.48, P < .001).
Table 4 shows the prognostic value of the chromatin entropy
marker within subgroups of primary and adjuvant treatment.
Discussion
There is currently no consensus on optimal treatment of uterine
sarcoma patients (21,22). Leiomyosarcomas, which is the most
common subtype, are very aggressive tumors and the influence
of adjuvant therapy on survival is uncertain (22). Radiotherapy
may be useful in controlling local recurrences, chemotherapy
with doxorubicin or docetaxel/gemcitabine is currently used for
advanced or recurrent disease, and some patients may respond
to hormonal treatment (22). The proposed new risk stratifica-
tion identified stage I leiomyosarcoma patients (medium and
high risk) who may be candidates for adjuvant chemotherapy.
Randomized clinical trials that evaluate the benefit of different
treatment strategies in these three risk groups are warranted.
The aim of surgery for early-stage ovarian cancer is to resect
the tumor and to undertake adequate staging (23). Relevant
postoperative treatment strategies for these patients are obser-
vation, single-agent carboplatin, and combination chemother-
apy, but there is no clear consensus regarding systemic
treatment (19). The European Society for Medical Oncology
(ESMO) recommends adjuvant chemotherapy to be offered to
suboptimally staged patients and also to optimally staged
patients at higher risk of recurrence (23), although also for
patients at low or medium risk, a small benefit of chemotherapy
cannot be excluded (19). Chromatin entropy offered prognostic
information in patients defined as high risk by stage and grade
(19,20), and could thus possibly aid in selecting patients who
could be treated with single-agent carboplatin and patients who
could be candidates for more aggressive combination chemo-
therapy. Chromatin entropy could also possibly be used to se-
lect low-risk patients who should be considered for adjuvant
chemotherapy, but this remains uncertain because our data did
Table 2. Multivariable time to recurrence analysis of the chromatin
entropy marker and established variables among 246 stage I ovarian
cancer patients*
Feature HR (95% CI) P†
Chromatin entropy .05
Low chromatin entropy Ref
High chromatin entropy 1.71 (1.01 to 2.90)
FIGO stage .008
Ia Ref
Ib–c 2.20 (1.23 to 3.96)
Histological grade <.001
1–2 Ref
3 or not graded (clear cell) 4.82 (2.79 to 8.34)
*Clear cell tumors are not graded at our institution, and because there was little
difference in time to recurrence between patients with clear cell and poorly dif-
ferentiated tumors, these patients were categorized together in previous analy-
ses (15). For the same reason, patients with FIGO stage Ib and Ic were
categorized together (15). CI ¼ confidence interval; HR ¼ hazard ratio.
†The P values were calculated using the two-sided Wald v2 test.
Figure 4. Kaplan-Meier recurrence-free survival curves among 246 early-stage ovarian cancer patients. Chromatin entropy is computed within the (A) combined low/
medium- and (B) high-risk groups, defined by stage and grade (19,20). High-risk ovarian carcinoma was defined as either clear cell histology, poorly differentiated tu-
mor, or the combination of moderately differentiated tumor and International Federation of Gynaecology and Obstetrics (FIGO) stage Ib or Ic; otherwise, the risk was
assessed as low (well-differentiated tumor and FIGO stage Ia) or medium (well-differentiated tumor and FIGO stage Ib or Ic, or moderately differentiated tumor and
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not allow reliable evaluation in this subgroup. Randomized clin-
ical trials are needed to assess the benefit of different chemo-
therapeutic regimes within groups defined by stage, grade, and
chromatin entropy.
One of the key challenges in clinical care of endometrial can-
cer patients is to correctly identify high-risk patients before pri-
mary surgery to more precisely tailor the surgical treatment and
thus avoid unnecessary invasive surgery of low-risk patients (24).
The established preoperative risk assessment based on histologi-
cal type and grade and diagnostic imaging (ultrasound, computed
tomography [CT], magnetic resonance imaging, positron emis-
sion tomography–CT) needs to be improved by including new
preoperative biomarkers (24). Within the group of patients de-
fined as low risk by curettage histology, high–chromatin entropy
patients had a statistically significantly higher risk for cancer-
specific death compared with low–chromatin entropy patients.
The hazard ratio increased within the group of low-risk patients
treated by hysterectomy without receiving adjuvant treatment,
also when stratifying on whether lymphadenectomy was per-
formed. The established treatment for presumed low-risk
patients is total hysterectomy with bilateral salpingo-
oophorectomy (24). Pelvic or para-aortic lymph node metastasis
occurs in 11% of presumed stage I endometrial carcinoma, and
therefore several centers have proposed extensive lymph node
sampling in all patients (25). However, the procedure for lympha-
denectomy is not standardized and is associated with increased
morbidity, and the benefits from this procedure are uncertain
(25). We suggest that chromatin entropy could be combined with
the preoperative curettage histology classification, such that
patients with low-risk curettage histology and low chromatin en-
tropy could be treated with total hysterectomy and bilateral
salpingo-oophorectomy alone, whereas patients with high-risk
curettage histology and/or high chromatin entropy could be re-
ferred to highly specialized units for more extensive surgery and
possibly adjuvant therapy, and warrant evaluation of such treat-
ment recommendations with respect to survival and cost-benefit
in randomized clinical trials.
As a part of the study design, the Nucleotyping biomarker
was developed on the uterine sarcoma discovery set, which is
the most different type of the three materials, and then evalu-
ated on two epithelial cancer validation sets, in addition to the
sarcoma validation set. Although all three materials are gyneco-
logical cancers located in the same area, they are histologically
very different and behave biologically very differently. However,
we have previously observed that the average difference in
chromatin structure between good and poor patients in each co-
hort was similar across the three cohorts (9–11). Based on these
observations, we wanted to evaluate the novel biomarker in all
three gynecological cohorts. The biomarker was not only a sta-
tistically significant prognostic marker in the sarcoma valida-
tion set, but also in the ovarian and endometrial cancer
validation sets. The ability to independently predict multiple
end points further demonstrates the robustness of the method.
This altogether indicates that the marker could easily and reli-
ably be measured in other laboratories and in clinical practice.
Table 4. Univariate cancer-specific survival analyses of the chromatin entropy marker among endometrial cancer patients within subgroups of
primary and adjuvant treatment*
Patient subgroups No. HR (95% CI) P†
5-y CSS (95% CI), %
LCE HCE
All patients 791 3.74 (2.24 to 6.24) <.001 87.5 (83.8 to 90.4) 65.8 (51.3 to 77.0)
Low-risk curettage histology 610 3.66 (1.52 to 8.80) .002 92.2 (88.5 to 94.7) 75.7 (53.3 to 88.4)
High-risk curettage histology 175 1.76 (0.93 to 3.35) .08 64.0 (51.0 to 74.4) 58.2 (37.7 to 74.0)
All patients treated with H 767 3.42 (1.94 to 6.05) <.001 88.5 (84.8 to 91.3) 70.3 (55.2 to 81.2)
Low-risk curettage histology 602 3.75 (1.56 to 9.04) .002 92.3 (88.6 to 94.8) 75.7 (53.3 to 88.4)
High-risk curettage histology 161 1.62 (0.76 to 3.45) .21 67.9 (54.2 to 78.3) 66.2 (43.7 to 81.5)
H þ no AT 526 12.70 (5.18 to 31.13) <.001 96.5 (93.5 to 98.1) 67.7 (45.1 to 82.6)
Low-risk curettage histology 464 18.38 (4.93 to 68.51) <.001 97.9 (94.8 to 99.2) 74.9 (45.6 to 89.9)
High-risk curettage histology 58 4.81 (1.35 to 17.23) .007 82.4 (62.7 to 92.2) 53.3 (17.7 to 79.6)
H þ no AT þ L 406 24.65 (7.13 to 85.26) <.001 97.6 (94.1 to 99.1) 70.4 (42.6 to 86.6)
Low-risk curettage histology 359 41.71 (6.96 to 250.00) <.001 98.7 (94.6 to 99.7) 75.0 (40.8 to 91.2)
High-risk curettage histology 44 6.38 (1.05 to 38.98) .02 86.7 (63.0 to 95.7) 62.5 (14.2 to 89.3)
H þ no AT þ no L 120 5.67 (1.41 to 22.79) .006 91.9 (81.7 to 96.6) 62.2 (21.3 to 86.4)
Low-risk curettage histology 105 3.96 (0.41 to 38.20) .20 94.5 (82.8 to 98.3) 75.0 (12.8 to 96.1)
High-risk curettage histology 14 3.01 (0.48 to 18.93) .21 70.0 (32.9 to 89.2) 33.3 (9.0 to 77.4)
*Curettage histology classified as low risk if benign, hyperplasia or endometrioid grade 1–2, and high risk if nonendometrioid or endometrioid grade 3. AT ¼ adjuvant
treatment; CI ¼ confidence interval; CSS ¼ cancer-specific survival; H ¼ hysterectomy; HCE ¼ high chromatin entropy; HR ¼ hazard ratio; L ¼ lymphadenectomy; LCE ¼
low chromatin entropy.
†The P values were calculated using the two-sided Mantel-Cox log-rank test.
Table 3. Multivariable cancer-specific survival analysis of the chro-
matin entropy marker and other preoperatively available variables
among 791 endometrial cancer patients
Feature HR (95% CI) P*
Chromatin entropy .009
Low chromatin entropy Ref
High chromatin entropy 2.03 (1.19 to 3.45)
Curettage histology† <.001
Low risk Ref
High risk 4.59 (2.92 to 7.23)
Age, y <.001
<66 Ref
66 2.75 (1.67 to 4.54)
*The P values were calculated using the two-sided Wald v2 test. CI ¼ confidence
interval; HR ¼ hazard ratio.
†Curettage histology classified as low risk if benign, hyperplasia or endometrioid
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Based on training in the discovery set, we selected a threshold
value on the proportion of high–chromatin entropy nuclei as high
as 25%. Univariate and multivariable five-year overall survival
analyses among sarcomas in the discovery set showed that the
prognostic value of the marker was higher for this threshold
value compared with threshold values in the interval defined by
average patient values (of proportions of high–chromatin entropy
nuclei) in the two prognostic groups. This observation indicates
that there is a relation between prognosis and a critical mass in
the proportion of high–chromatin entropy nuclei.
The biomarker had a high specificity and a low sensitivity.
Although the marker identified only small subgroups of
patients who had a poor prognosis, it added prognostic informa-
tion within several subgroups of both low-risk and high-risk
patients defined by established biomarkers and clinically rele-
vant risk stratifications.
The Nucleotyping biomarker is based on the same high-
resolution digital images used in the well-known DNA image cy-
tometry method for measuring nuclear DNA content, which is a
relatively simple, inexpensive, and robust methodology that can
easily be automated (3). Both aneuploidy and chromatin entropy
are markers for large-scale genomic instability, but while DNA
ploidy measures the overall amount of nuclear DNA,
Nucleotyping measures changes in the chromatin structure. The
proportions of gynecological cancer patients classified as aneu-
ploid (14–16) are relatively large compared with the small sub-
groups of patients classified as high chromatin entropy. Further
analyses of the high–chromatin entropy nuclei are needed to gain
more insight into the underlying mechanisms and the contribu-
tion of these cells to carcinogenesis and metastatic potential.
The main limitation with this study is that the benefit of dif-
ferent treatment strategies in the proposed risk groups based
on chromatin entropy and established clinicopathological
parameters are not evaluated in randomized clinical trials.
In conclusion, a novel method for detecting high–chromatin
entropy nuclei was developed, and the proportion of such devi-
ating nuclei per patient was a statistically significant prognostic
marker in three gynecological cancer cohorts and could be used
as a supplement in defining high-risk patients.
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